New Data Presented on ASLAN’s varlitinib at ESMO 2019
October 02, 2019 02:30 ET
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the presentation of...
ASLAN Pharmaceuticals and Bukwang Pharmaceutical Establish a Joint Venture, JAGUAHR Therapeutics, to Develop Novel Immuno-Oncology Therapies
September 30, 2019 02:35 ET
|
ASLAN PHARMACEUTICALS LIMITED
- ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to US$5 million - ASLAN and Bukwang will co-own new entity to develop novel...
ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO
September 19, 2019 03:50 ET
|
ASLAN PHARMACEUTICALS LIMITED
- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8...
New Data From Aslan’s Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting
August 27, 2019 06:00 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Aug. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that a late-breaking...
ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 13, 2019 04:03 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
ASLAN Pharmaceuticals Names Industry Veteran and Current Board Member Andrew Howden to Additional Role of Chairman
July 26, 2019 04:20 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, July 26, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that Andrew Howden...
ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis
June 04, 2019 08:00 ET
|
ASLAN Pharmaceuticals Limited
- Final results from single ascending dose study confirm ASLAN004’s favourable tolerability profile, complete inhibition of downstream mediators and potential for monthly dosing SINGAPORE, June ...
ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL
May 31, 2019 03:15 ET
|
ASLAN Pharmaceuticals Limited
- Amending their previous agreement, CSL grants ASLAN full global rights to develop, manufacture and commercialise ASLAN004 SINGAPORE, May 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals...
ASLAN Pharmaceuticals’ Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer
May 10, 2019 04:15 ET
|
ASLAN Pharmaceuticals Limited
- K-MASTER, Korea’s leading precision medicine research group, to conduct phase 1b/2 umbrella study testing varlitinib as a second-line treatment in HER1/HER2 co-expressing advanced or metastatic...
ASLAN Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
April 29, 2019 05:02 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, April 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical stage oncology and immunology focused biopharmaceutical company developing novel therapeutics...